JAK2 and rheumatoid arthritis: This can be further explained by the findings of [45], who reported that the inactivation of both JAK1 and JAK2 produced by baricitinib resulted in the inhibition of the process of subchondral bony erosions and, subsequently, the radiographic disease progression in RA patients.